Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-10: belantamab mafodotin + lenalidomide + dexamethasone versus daratumumab + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
CTR20250279Phase 3Active
- Sponsor
- GSK
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Apr 2025; status: active.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20250279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250279.